Literature DB >> 3184160

Antitumor and antimicrobial activities of lipid A-subunit analogue GLA-27.

M Nakatsuka1, Y Kumazawa, S Ikeda, A Yamamoto, C Nishimura, J Y Homma, M Kiso, A Hasegawa.   

Abstract

Activities for enhancing nonspecific host resistance against microbial infections and growth inhibition against tumors by a lipid A-subunit analogue GLA-27 were investigated. GLA-27, a 4-O-phosphono-D-glucosamine derivative with 2-N-3-tetradecanoyloxytetradecanoyl and 3-O-tetradecanoyl group, inhibited significantly the growth of solid-type tumors RL male 1 lymphoma and Meth A fibrosarcoma. In the case of RL male 1 lymphoma, 2.5 micrograms of GLA-27 was needed to exhibit the activity, while for Meth A fibrosarcoma, 250 micrograms of GLA-27 was needed. On the other hand, tail lesions induced by intravenous inoculation with vaccinia virus were effectively suppressed in mice injected with 1 microgram of GLA-27 1 day before the viral injection. The antiviral activity of GLA-27 was 100 times higher than that of MDP by ED50. GLA-27 also showed nonspecific protective activity against Pseudomonas aeruginosa infection at a dose of 30 micrograms/mouse, although the activity was far less than that induced by lipid A. GLA-27 did not exhibit toxic activities such as pyrogenicity and Shwartzman reaction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3184160

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  2 in total

1.  Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats.

Authors:  N Onier; S Hilpert; L Arnould; V Saint-Giorgio; J G Davies; J F Jeannin; J F Jeannin
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

2.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.